A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
40actual
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-28 | actual | When the study began enrolling |
| Primary completion | 2025-03-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-04 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: REGN17092
- Drug: Matching Placebo
Primary outcomes
what the primary-completion date above is the date OFOccurrence of all treatment emergent adverse events (TEAEs)
measured Through approximately day 365
Severity of all TEAEs
measured Through approximately day 365
Occurrence of all treatment emergent serious adverse events (TE-SAEs)
measured Through approximately day 365
Severity of all TE-SAEs
measured Through approximately day 365
Posted documents
hosted by the registry — we link, never re-serveInformed Consent Formposted 2023-08-01 · 370 KB · ICF_000.pdf
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed